

**Zoono Group Limited (ASX: ZNO)
ASX ANNOUNCEMENT**

19 February 2020

NZ\$3.5m in sales revenues to date in the current quarter

Further to the release of the December half year financial report of Zoono Group Limited (Company) (ASX: ZNO), in response to the unprecedented level of interest in the Company and its products, the Company is delighted to advise that revenues (unaudited) for the current quarter (7 weeks only) are NZ\$3.5 million (which compares extremely favourably to revenues of NZ\$1.715M for the whole of the first half of FY20).

In addition to the above, the Company is also able to report:

- its available cash resources have increased to in excess of NZ\$4.0 million (an increase of over NZ\$1.0m from 31 December 2019);
- Online sales are now averaging NZ\$30,000 to NZ\$50,000 per day;
- The percentage gross margin on sales is also increasing in line with the growth in sales revenues; and
- Work is progressing on a number of further significant potential transactions for the distribution and/or supply of the Company's products as interest in these products and the Company's technology spreads around the globe.

Details of these further initiatives will be announced to the market once negotiations are concluded.

With the global impact of the coronavirus outbreak (COVID-19), and the efficacy of Zoono's technology and products against viruses and bacteria, the major issue facing the Company this year has been how to cope with the influx of orders and the expectation, derived directly from the level of enquiry from across the globe, of substantial prospective new orders.

To keep ahead of the game and ahead of orders, the Company is undertaking the following initiatives.

- Ramped up production (to enable seven-day order fulfilment whenever practicable)
- Relocating to a substantially larger (x3) warehouse and office facility (in early March 2020)
- Ordering 4 million bottles to keep up with demand
- Increased raw material supplies to make 3 million litres of products
- Hiring more staff to cope with the increased demand

This announcement has been authorised and approved for release to ASX by the Board of Zoono Group Limited.

For further information, please contact:

Zoono Group Limited

Paul Ravlich

CFO

M: +64 21 0759 176

E: paul.ravlich@zoono.com.

About Zoono

Zoono Group Limited is a global biotech company that develops, manufactures and distributes a suite of scientifically-validated, long-lasting and environmentally-friendly antimicrobial solutions. Zoono's mission is to improve health and well-being through innovative, safe, non-toxic and durable germ protection.

Zoono produces sprays, wipes and foams suited for skin care, surface sanitisers, and mould remediation treatments. The products are based on the 'zoono molecule', a unique antimicrobial molecule that bonds to any surface and kills pathogens including bacteria, viruses, algae, fungi and mould.

Zoono's products have received numerous regulatory approvals and the company's technology claims are supported by independent testing conducted in laboratories worldwide. Zoono is headquartered in New Zealand and its products are available globally.

To learn more, please visit: www.zoono.com